Pfizer (NYSE:PFE) Given a $45.00 Price Target at UBS Group

UBS Group set a $45.00 price objective on Pfizer (NYSE:PFE – Get Rating) in a research report report published on Tuesday, Borsen Zeitung reports.

A number of other analysts have also recently issued reports on the stock. Bank of America cut shares of Pfizer from a buy rating to a neutral rating and set a $60.00 price objective for the company. in a research note on Wednesday, January 4th. The Goldman Sachs Group upgraded shares of Pfizer from a neutral rating to a buy rating and upped their target price for the stock from $47.00 to $60.00 in a research report on Tuesday, December 13th. SVB Leerink dropped their target price on shares of Pfizer from $49.00 to $48.00 and set a market perform rating for the company in a research report on Wednesday, February 1st. Morgan Stanley dropped their target price on shares of Pfizer from $53.00 to $45.00 and set an equal weight rating for the company in a research report on Wednesday, February 1st. Finally, Cantor Fitzgerald restated an overweight rating and set a $75.00 target price on shares of Pfizer in a research report on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and an average price target of $50.75.

Pfizer Stock Up 0.1 %

Shares of PFE stock opened at $39.90 on Tuesday. Pfizer has a 12 month low of $39.23 and a 12 month high of $56.32. The stock has a market cap of $224.20 billion, a P/E ratio of 7.28, a P/E/G ratio of 1.31 and a beta of 0.64. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The company has a 50 day simple moving average of $43.86 and a two-hundred day simple moving average of $46.16.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.08 earnings per share. On average, research analysts expect that Pfizer will post 3.33 earnings per share for the current year.

Institutional Investors Weigh In On Pfizer

Institutional investors have recently made changes to their positions in the company. Front Street Capital Management Inc. increased its stake in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 215 shares during the period. Lindenwold Advisors increased its stake in Pfizer by 1.0% in the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 216 shares during the period. SRS Capital Advisors Inc. increased its stake in Pfizer by 1.6% in the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock worth $714,000 after buying an additional 218 shares during the period. Wagner Wealth Management LLC increased its stake in Pfizer by 0.9% in the 2nd quarter. Wagner Wealth Management LLC now owns 24,756 shares of the biopharmaceutical company’s stock worth $1,298,000 after buying an additional 219 shares during the period. Finally, Signet Financial Management LLC increased its position in Pfizer by 0.6% during the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock valued at $1,503,000 after purchasing an additional 220 shares during the period. Institutional investors own 67.62% of the company’s stock.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.